Celgene planning regulatory submissions for Revlimid in indolent lymphoma on Phase III win

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab met the primary endpoint of improving progression-free

Read the full 160 word article

User Sign In